Cuál es el precio por Fresh Tracks Therapeutics, Inc. (FRTX)

Precio por Fresh Tracks Therapeutics, Inc. (FRTX) es de$0.94

Cuál es la capitalización de mercado por Fresh Tracks Therapeutics, Inc. (FRTX)

Capitalización de mercado por Fresh Tracks Therapeutics, Inc. (FRTX) es $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) EPS

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

Año	EPS	Cambiar
2026 (TTM)	$-1.40	45.83%
2023	$-0.96	-86.96%
2022	$-7.36	-66.76%
2021	$-22.14	-42.30%
2020	$-38.37	-90.06%
2019	$-386.21	64.76%
2018	$-234.41	-26.00%
2017	$-316.76	12.28%
2016	$-282.12	-11.05%
2015	$-317.17	-45.79%
2014	$-585.11	-48.36%
2013	$-1.13K	35.04%
2012	$-839.10	163.45%
2011	$-318.51	-80.01%
2010	$-1.59K	-16.62%
2009	$-1.91K	-34.48%
2008	$-2.92K	1.08%
2007	$-2.89K	24.38%
2006	$-2.32K	-25.69%
2005	$-3.12K	-5.25%
2004	$-3.29K	-14.06%
2003	$-3.83K	-12.52%
2002	$-4.38K	201.59%
2001	$-1.45K	6.63%
2000	$-1.36K	0.00%

Año

EPS

Cambiar

2026 (TTM)

$-1.40

45.83%

2023

$-0.96

-86.96%

2022

$-7.36

-66.76%

2021

$-22.14

-42.30%

2020

$-38.37

-90.06%

2019

$-386.21

64.76%

2018

$-234.41

-26.00%

2017

$-316.76

12.28%

2016

$-282.12

-11.05%

2015

$-317.17

-45.79%

2014

$-585.11

-48.36%

2013

$-1.13K

35.04%

2012

$-839.10

163.45%

2011

$-318.51

-80.01%

2010

$-1.59K

-16.62%

2009

$-1.91K

-34.48%

2008

$-2.92K

1.08%

2007

$-2.89K

24.38%

2006

$-2.32K

-25.69%

2005

$-3.12K

-5.25%

2004

$-3.29K

-14.06%

2003

$-3.83K

-12.52%

2002

$-4.38K

201.59%

2001

$-1.45K

6.63%

2000

$-1.36K

0.00%

Empresa	EPS	Diferencia de EPS	País
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-1,337.14%	US
Argenx SE ARGX.US	$27.74	-2,081.43%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-1,078.58%	BE

Empresa

EPS

Diferencia de EPS

País